Valuation: Zentalis Pharmaceuticals, Inc.

Market Cap 332M 292M 273M 250M 468M 31.84B 480M 3.23B 1.26B 15.76B 1.25B 1.22B 54.47B P/E 2026 *
-2.54x
P/E 2027 * -2.86x
Enterprise Value 121M 106M 99.2M 91.04M 170M 11.58B 175M 1.18B 460M 5.73B 454M 444M 19.82B EV / Sales 2026 *
-
EV / Sales 2027 * 7.28x
Free-Float
77.16%
Yield 2026 *
-
Yield 2027 * -
1 day+1.08%
1 week+3.78%
Current month-3.71%
1 month+1.30%
3 months+17.93%
6 months+86.06%
Current year+245.93%
1 week 4.13
Extreme 4.1313
4.74
1 month 4.13
Extreme 4.1313
5.58
Current year 1.32
Extreme 1.32
6.95
1 year 1.21
Extreme 1.212
6.95
3 years 1.01
Extreme 1.01
29.03
5 years 1.01
Extreme 1.01
87.19
10 years 1.01
Extreme 1.01
87.19
Manager TitleAgeSince
Chief Executive Officer 62 2024-11-12
Director of Finance/CFO - 2024-11-12
Chief Tech/Sci/R&D Officer 51 2024-11-12
Director TitleAgeSince
Chairman 61 2022-05-15
Director/Board Member 44 2021-02-08
Director/Board Member 59 2022-09-11
Date Insider Type Main position Quantity % Market Cap.
6/16/26 Free

Director

57,100 0.0802%
6/16/26 Free

Director

57,100 0.0802%
6/16/26 Free

Chairman

57,100 0.0802%
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+3.78%+245.93%-82.54% 329M
+0.47%+2.27%+50.78%+70.84% 55.01B
+2.83%+0.48%+28.18%+82.59% 54.24B
+0.54%+1.22%-16.62%-13.47% 23.38B
-0.97%-3.30%-1.79%+383.00% 22.57B
-2.49%+1.39%+17.20%-9.05% 20.19B
-2.15%-2.30%+27.27%-31.03% 17.86B
-1.65%-3.75%+26.23%+536.72% 15.5B
-2.09%+0.64%+49.78%+178.74% 14.2B
-3.14%-8.47%+165.37%+292.18% 14.2B
Average -0.35%-1.28%+59.23%+140.80% 23.75B
Weighted average by Cap. +0.28%-0.12%+34.82%+130.32%

Financials

2026 *2027 *
Net sales - 19.28M 16.94M 15.81M 14.51M 27.16M 1.85B 27.83M 187M 73.32M 914M 72.37M 70.8M 3.16B
Net income -151M -132M -124M -113M -212M -14.44B -218M -1.47B -573M -7.15B -566M -554M -24.7B -155M -136M -127M -117M -218M -14.83B -224M -1.51B -589M -7.34B -581M -569M -25.37B
Net Debt -211M -186M -173M -159M -298M -20.26B -305M -2.06B -804M -10.02B -794M -777M -34.65B -192M -169M -158M -145M -271M -18.41B -277M -1.87B -731M -9.11B -722M -706M -31.49B
Logo Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Employees
106
Date Price Change Volume
26-07-29 US$4.670 +1.08% 709,431
26-07-28 US$4.620 +2.44% 1,214,475
26-07-27 US$4.510 +4.16% 1,029,574
26-07-24 US$4.330 -2.70% 1,212,587
26-07-23 US$4.450 -1.11% 992,448
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
4.670USD
Average target price
6.667USD
Spread / Average Target
+42.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZNTL Stock